A Phase III, Multicenter, Randomized, Open Label, Clinical study To evaluate Efficacy and Safety of two strengths of Meropenem Plus Tazobactam For the Treatment of Patients with Gram Negative Infection Including Pseudomonas aeruginosa
Latest Information Update: 15 Sep 2020
At a glance
- Drugs Meropenem/tazobactam (Primary) ; Meropenem
- Indications Escherichia coli infections; Gram-negative infections; Pseudomonal infections
- Focus Registrational; Therapeutic Use
- Sponsors Aqua Vitoe Laboratories
- 05 May 2013 Status changed from recruiting to completed as reported by Clinical Trials Registry - India.
- 12 Mar 2013 New trial record